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Objectives: The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-
inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the
treatment of MRSA infection.
Methods: We conducted a randomized, open-label, single-centre, non-inferiority trial comparing trimethoprim/
sulfamethoxazole (160 mg/800 mg three times daily) plus rifampicin (600 mg once a day) versus linezolid
(600 mg twice a day) alone in adult patients with various types of MRSA infection. Patients were allocated 1:1
to either regimen. The primary outcome was clinical cure at 6 weeks after the end of treatment (non-inferiority
margin 20%) assessed by both ITT and PP analyses. Secondary outcomes included the microbiologically
documented persistence of MRSA in clinical cultures, mortality and adverse events. The study protocol has
been registered with ClinicalTrials.gov (NCT00711854).
Results: Overall, 150 patients were randomized to one of the two treatment arms between January 2009 and
December 2013 and were included in the ITT analysis. Of these 56/75 (74.7%) in the linezolid group and 59/75
(78.7%) in the trimethoprim/sulfamethoxazole and rifampicin group experienced clinical success (risk difference
4%, 95% CI29.7% to 17.6%). The results were confirmed by the PP analysis, with 54/66 (81.8%) cured patients
in the linezolid group versus 52/59 (88.1%) in the trimethoprim/sulfamethoxazole and rifampicin group (risk
difference 6.3%, 95% CI 26.8% to 19.2%). There were no statistically significant differences between the two
groups in any of the secondary outcomes, including microbiologically documented failure. Four adverse drug
reactions attributed to the study medication occurred in the linezolid group versus nine in the trimethoprim/
sulfamethoxazole and rifampicin group.
Conclusions: Compared with linezolid, trimethoprim/sulfamethoxazole and rifampicin seems to be non-inferior
in the treatment of MRSA infection.
Keywords: adults, Switzerland, humans, prospective clinical studies, staphylococcal infections, drug therapy, multidrug-resistant
organisms
Introduction
Infections caused by Staphylococcus aureus represent an
important therapeutic challenge. The treatment most frequently
recommended for severe infection due to MRSA is a prolonged
course of parenteral vancomycin.1 However, vancomycin treat-
ment increases healthcare costs because of the prolonged hos-
pital stay and exposes patients to complications associated with
venous lines, renal toxicity and the need for therapeutic drug
monitoring. Alternative treatment regimens with oral antibiotics
(e.g. fluoroquinolone and rifampicin for MSSA or linezolid for
MRSA) have been proposed.2,3 The use of older antimicrobial
agents such as minocycline or trimethoprim/sulfamethoxazole,
combined with rifampicin or fusidic acid, may represent particu-
larly interesting treatment alternatives for both community-
and healthcare-associated MRSA infections.1,4,5 The only
anti-MRSA antibiotic agent that has undergone in-depth clinical
evaluation in its oral formulation is linezolid.6 Its use is, however,
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limited by its cost and the possible drug interactions and adverse
events (AEs) associated with long-term therapy.7,8 This leaves an
unmet clinical need for the evaluation of other oral anti-MRSA
therapies. Therefore, we performed a randomized non-inferiority
trial to compare the efficacy and safety of therapy with trimetho-
prim/sulfamethoxazole plus rifampicin versus linezolid alone to
treat MRSA infection.
Methods
Trial design
This was an investigator-initiated, open-label, single-centre, randomized
clinical trial to demonstrate the non-inferiority of a combination of
trimethoprim/sulfamethoxazole plus rifampicin versus linezolid in patients
(allocation ratio 1:1) requiring antibiotic therapy for MRSA infection. The
study protocol was approved by the local institutional review board (no.
08-59) and the Swiss agency for therapeutic products (SwissMedic
no. 2008DR4305), and has been registered with ClinicalTrials.gov
(NCT00711854). Written consent was obtained from all participants.
Setting and participants
This study was conducted at the Geneva University Hospitals, a Swiss
tertiary care centre with 1915 beds, 48000 yearly admissions and
hyperendemic MRSA transmission.9 Antibiotic susceptibility data in 2011
revealed that MRSA isolates from clinical cultures were 97%, 97%, 11%,
97%, 100% and 100% susceptible to trimethoprim/sulfamethoxazole,
rifampicin, clindamycin, fusidic acid, linezolid and vancomycin, respectively.
Between January 2009 and December 2013, we enrolled patients aged
≥18 years and able to provide informed consent, who had clinical signs
and symptoms of MRSA infection according to clinical culture results
(MRSA as the predominant or unique microorganism in culture) that was
susceptible to trimethoprim/sulfamethoxazole, rifampicin and linezolid.
Standard microbiology methods were used for MRSA identification and
antimicrobial susceptibility testing, which was performed both phenotyp-
ically (using the disc diffusion method, interpreted with CLSI breakpoints)
and genotypically (femA andmecA determination, using the BD GeneOhm
MRSA assay).10
Various types of MRSA infection, including severe infections (e.g.
pneumonia, bacteraemia), deep-seated infections requiring treatment
for more than 14 days (e.g. osteoarticular infections) and non-severe
infections (of skin and soft tissue) requiring shorter courses of treatment
could be included. Potentially eligible patients were identified by daily
surveys and an electronic alert of all MRSA-positive cultures generated
by the clinical microbiology laboratory.10
Patients who had been treated for ≥72 h prior to study inclusion with
antimicrobials active against MRSA (mostly vancomycin) were excluded.
Additional exclusion criteria were: known hypersensitivity to linezolid, tri-
methoprim/sulfamethoxazole or rifampicin; pregnancy or breastfeeding;
significant impairment of hepatic function; haemodialysis; severe
thrombocytopenia (,50000 platelets/mL); chronic MRSA osteomyelitis
without surgical debridement; a superinfected indwelling foreign body
kept in place; severe sepsis or septic shock due to MRSA bacteraemia;11
left-sided endocarditis; oral contraception; a history of phaeochromocy-
toma, carcinoid syndrome or untreated hyperthyroidism; or being in
receipt of serotonergic agents.
Interventions
Patients randomized to the trimethoprim/sulfamethoxazole plus rifampi-
cin arm received oral therapy or intravenous infusion (with a suggested
maximum duration of 5 days) of 160 mg of trimethoprim and 800 mg
of sulfamethoxazole three times daily and 600 mg of rifampicin once
daily. Patients randomized to the linezolid arm received oral therapy (or
an intravenous infusion) of 600 mg of linezolid twice daily. The treatment
was administered for at least 7 days, depending on the type and severity of
the MRSA infection. MRSA infection types were classified by the involved
study physicians in agreementwith the treating clinicians, based on clinical,
bacteriological and radiological criteria. For each category, the minimum
recommended duration of treatment was defined as follows: non-severe
infections (e.g. urinary tract infections, soft tissue infections), 7–10 days;
severe infections (e.g. pneumonia, bacteraemia), 14 days; and infections
associated with deep-seated foci, 14–42 days. Any discontinuation or
modification of antimicrobial therapy was left to the judgement of the
treating physicians. In cases of polymicrobial infection not covered by the
study treatment, physicians were able to add concomitant systemic anti-
biotic treatmentwithout anti-MRSA activity if thiswas considered to be clin-
ically indicated.
Outcomes
Assessments of bacteriological results, clinical signs and symptoms of
infection, as well as clinical and laboratory safety evaluations, were
made at study entry and at the end of the treatment (+48 h). Final evalu-
ation was made by one of the study physicians 6 weeks (+1 week) after
the patient had received the final dose of the trial treatment. If the patient
could not be reached for the final assessment, telephone contact and
evaluation by the general practitioner in chargewere considered sufficient.
The primary efficacy variable was the resolution of MRSA infection at
6 weeks after the end of treatment, defined as the resolution of all the
clinical signs and symptoms of the infection that had been present at
baseline;2 failure was defined as no improvement or a deterioration in
the clinical condition or a change of the allocated treatment regimen at
any time or the death of the patient. We determined the final outcome
using all the available information, including subsequent radiographic
exams, microbiology results, surgical interventions and the patient’s clin-
ical course. Bacteriological cure as a secondary outcome was defined as
the eradication of MRSA from the infection site. Bacteriological failure
was defined as a microbiologically documented persistence or relapse of
MRSA at the same site as the original isolate. Other secondary outcomes
were all-cause mortality and length of hospital stay after randomization.
All included patients were monitored for AEs, serious AEs (SAEs) and
adverse drug reactions (ADRs). An ADR was defined as harm causally
related to the administration of the study medication at a normal dosage.
Toxicity was reported to be causally related to the study antibiotics if it
began when the drugs were first administered, abated after the discon-
tinuation of drug use and was not clearly attributable to other causes.
Randomization
As soon as the results of antimicrobial susceptibility testing were available,
and provided the enrolment criteria had been fulfilled, the patient and the
medical staff responsible for the treatment were contacted by the study
investigators. Patients who fulfilled the inclusion criteria were randomly
assigned by sealed, opaque, numbered envelopes to one of the two
treatment arms. The sequence was generated using an internet-based
randomization generator with a block size of 30.
Sample size
This non-inferiority trial attempted to ascertain whether the clinical effi-
cacy of treating MRSA infections with trimethoprim/sulfamethoxazole
plus rifampicin was comparable to that of linezolid. The 95% CI for the
difference in success rates (percentage cure at 6 weeks after the end of
treatment in the trimethoprim/sulfamethoxazole plus rifampicin arm
minus the percentage cure in the linezolid arm) was calculated on the
basis of the normal approximation to the binomial distribution.12 The non-
inferiority test was based on the lower boundary of the 95% CIs for a
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clinically important difference in success rates and settled within the non-
inferiority margin of 20% and the upper boundary containing 0% (e.g. a
difference of 20% in the clinical efficacy of the two antibiotic regimens
would justify the use of one over the other). This margin was based not
only on acceptable differences in cure rates, but also on considerations
of treatment costs and study feasibility. Assuming a 75% efficacy in
both treatment groups,3,13,14 a statistical power of 80% and a one-sided
significance level of 0.025, we estimated that 90 evaluable patients
needed to be enrolled in each treatment group to test the null hypothesis
(that the treatment success rates would differ by .20%).
Statistical methods
Two different patient populations were analysed: the ITT patient popula-
tion and the PP population of completely evaluable patients. The ITT
population included all the patients who had been randomized. For the
ITT analysis, 13 patients lost to follow-up were assigned to the outcome
‘failure’. Patients entered the PP analysis if they had received study drugs
for at least 7 days and were fully clinically evaluable at the last follow-up
visit.2
For hypothesis testing, we used the Student’s t-test for normally dis-
tributed variables, the two-sample Wilcoxon rank-sum test for skewed
distributions and the Fisher’s exact test or w2 test for the homogeneity
of proportions for categorical data. Statistical analyses were performed
using Stata version 12 (Stata Corp., College Station, TX, USA).
Results
Participant flow and recruitment
The study groups and reasons for non-inclusion are shown in
Figure 1. Therewere 1638 patientswith at least oneMRSA-positive
clinical culture during the study period. Of these, 164 (10.0%)
were deemed to be eligible after a chart review and were invited
to participate; 150 (9.2%) agreed to participate in the study, pro-
vided written consent and were randomized, with 75 patients
1638 patients with current MRSA-positive clinical culture between 01/2009 and 12/2013
567 patients infected and
treated with a systemic
antibiotic active against MRSA
1071 patients excluded
(patients not treated with systemic
antibiotics)
417 patients excluded:
• 14 study proposed but declined 
• 403 ≥1 exclusion criteria present 
150 patients
signed informed consent and 
randomized
75 patients*
linezolid
75 patients*
SXT/rifampicin
9 patients excluded:
• 2 had <7 days of treatment and lost to
follow-up
• 3 had <7 days of treatment
• 4 lost to follow-up
66 patients
linezolid
59 patients
SXT/rifampicin
ITT analysis
PP analysis
16 patients excluded:
• 1 had <7 days of treatment and lost to
follow-up
• 9 had <7 days of treatment
• 6 lost to follow-up
Figure 1. Trial profile. *All patients received the allocated regimen. SXT, trimethoprim/sulfamethoxazole.
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Table 1. Baseline characteristics by treatment assignment (all randomized patients)
Linezolid group (n¼75)
Trimethoprim/sulfamethoxazole
and rifampicin group (n¼75)
Male, n (%) 50 (66.7) 52 (69.3)
Age (years), median (IQR) 69 (56–76) 67 (50–80)
Type of admission, n (%)
emergency 47 (62.7) 51 (68.0)
elective 23 (30.7) 16 (21.3)
outpatient 5 (6.7) 8 (10.7)
Prior hospitalization in a long-term care facility, n (%) 20 (26.7) 25 (33.3)
Hospital unit at the time of inclusion, n (%)
surgery 43 (57.3) 37 (49.3)
medicine 13 (17.3) 14 (18.7)
long-term and geriatric care 4 (5.3) 8 (10.7)
ICU 3 (4.0) 5 (6.7)
other 7 (9.3) 3 (4.0)
ambulatory 5 (6.7) 8 (10.7)
Comorbidities, n (%)
cardiovascular 47 (62.7) 47 (62.7)
pulmonary 13 (17.3) 11 (14.7)
renal 16 (21.3) 14 (18.7)
metabolic 22 (29.3) 19 (25.3)
malignancy 20 (26.7) 18 (24.0)
digestive 9 (12.0) 3 (4.0)
immunological 1 (1.3) 4 (5.3)
other diseases 28 (37.3) 31 (41.3)
surgical interventionsa 54 (72.0) 41 (54.7)
Degree of dependency on admission, n (%)
independentb 55 (73.3) 42 (56.0)
semi-dependent 13 (17.3) 21 (28.0)
dependent 7 (9.3) 12 (16.0)
Charlson score, median (IQR) 5 (2–7) 4 (1–7)
McCabe score (underlying disease), n (%)
non-fatal condition 58 (77.3) 58 (77.3)
ultimately fatal condition 13 (17.3) 13 (17.3)
rapidly fatal condition 4 (5.3) 4 (5.3)
Polymicrobial infection with MRSA as dominant pathogen, n (%) 23 (30.7) 13 (17.3)
History of known MRSA carriage, n (%) 59 (78.7) 51 (68.0)
MRSA infection source, n (%)
skin and soft tissue infection 21 (28.0) 24 (32.0)
surgical site infection 19 (25.3) 15 (20.0)
bacteraemia 9 (12.0) 9 (12.0)
nosocomial pneumonia 8 (10.7) 9 (12.0)
osteoarticular 9 (12.0) 7 (9.3)
abdominal 4 (5.3) 3 (4.0)
urinary tract infection 2 (2.7) 5 (6.7)
other 3 (4.0) 3 (4.0)
Prior antibiotic treatment
patients receiving at least one dose of empirical anti-MRSA antibiotic
therapy before study inclusion, n (%)
40 (53.3) 29 (38.7)
time from start of empirical anti-MRSA antibiotic therapy to study inclusion (days),
median (IQR)
1 (0–3) 0 (0–2)
aP¼0.028.
bP¼0.026.
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included in each study arm (the ITTpopulation). Of note, the study
was stopped after 150 patients because of recruitment problems
due to the substantially decreased incidence of MRSA infections at
our institution.
Overall, 25 patients were excluded from the PP analysis: 12
patients because of ,7 days of study treatment, 10 patients for
not having a complete follow-up and 3 patients for both reasons
(Figure 1).
Baseline data
Baseline characteristics were comparable between the two study
groups, except that patients in the linezolid group underwent
statistically significantlymore surgical interventions (54/75 versus
41/75) and were more likely to be living independently at home
(55/75 versus 42/75; Table 1). The mean age of the patients
was 64 years (range 18–95 years), and 102/150 (68.0%) were
male. A majority of patients (53.3%) were hospitalized in the sur-
gical department. The leading primary sites of MRSA infection
were skin and soft tissue (30%) and surgical sites (23%), which
were equally distributed in the two study arms.
Antibiotic treatment
In both treatment groups, similar proportions of patients received
empirical anti-MRSA antibiotic therapy for up to 72 h before study
inclusion (Table 1). After study inclusion, 32 patients received
concomitant non-investigational antimicrobial therapy without
anti-MRSA activity, with comparable frequencies between the
study arms (Table 2).
The total duration of study treatment was similar in the two
study groups (Table 2). Only 29 patients (19.3%) received ≥1
dose of intravenous study treatment. The proportion of patients
who prematurely discontinued the assigned study medication,
as well as the reasons for their premature withdrawal, were com-
parable between the treatment groups (Table 2).
Efficacy
The clinical response rates provided by the ITT and PP analyses
demonstrated that trimethoprim/sulfamethoxazole and rifam-
picin produced success rates comparable to those of linezolid
treatment (Table 3). In the ITT analysis, 56/75 (74.7%) linezolid-
treated patients and 59/75 (78.7%) of patients receiving tri-
methoprim/sulfamethoxazole and rifampicin achieved clinical
success, with an absolute difference in success rates of +4%
(95% CI 29.7% to 17.6%). Since the lower boundary (29.7%)
was within the predefined margin (220%), the non-inferiority
of trimethoprim/sulfamethoxazole and rifampicin could be
demonstrated.
The PP analysis confirmed the ITT results, with 54/66 (81.8%)
of patients in the linezolid group achieving clinical success versus
52/59 (88.1%) in the trimethoprim/sulfamethoxazole and rifam-
picin group (risk difference +6.3%, 95% CI 26.8% to 19.2%). The
microbiological success rates among the 58 patients with
available follow-up cultures were also similar in the two groups
in the PP analysis, with proven eradication of MRSA in 26/33
(78.8%) patients in the linezolid group and 22/25 (88.0%) in the
trimethoprim/sulfamethoxazole and rifampicin group (risk differ-
ence +9.2%, 95% CI 212.0% to 28.4%; P¼0.09). No selection of
resistance to the study drugs was observed among the follow-up
MRSA cultures.
Table 4 shows the post hoc subgroup analyses by site and
severity of MRSA infection, revealing small differences in success
rates except for pneumonia and osteoarticular infection.
Mortality and length of stay
Eight patients in the linezolid group and six patients in the tri-
methoprim/sulfamethoxazole and rifampicin group died before
end of follow-up (P¼0.78). Among the 18 patients with MRSA
bacteraemia, 4 died (2 in each arm). One death in the linezolid
arm was directly attributable to MRSA bacteraemia and subse-
quent therapeutic withdrawal. There was no significant difference
Table 2. Study treatment description
Linezolid group (n¼75)
Trimethoprim/sulfamethoxazole
and rifampicin group (n¼75) P
Total study treatment duration (days), median (IQR) 12 (8–15) 11 (8–15) 0.48
oral study treatment duration (days), median (IQR) 12 (8–15) 10 (7–14.5) 0.63
Intravenous study treatment
patients receiving at least one dose of intravenous study treatment, n (%) 11 (14.7) 18 (24.0) 0.21
delay before intravenous–oral switch (days), median (IQR) 1 (1–11) 6 (3–7) 0.84
intravenous study treatment duration (days), median (IQR) 6.5 (5–7) 12.5 (1–24) 0.14
Patients with concomitant systemic antibiotic treatment without anti-MRSA
activity, n (%)
14 (18.7) 18 (24.0) 0.55
Patients who prematurely discontinued study therapy, n (%) 7 (9.3) 12 (16.0) 0.33
Reason for premature discontinuation, n (%)
drug toxicity 3 (4.0) 6 (8.0) 0.49
clinical failure 1 (1.3) 2 (2.7) 1.00
death 2 (2.7) 4 (5.3) 0.68
protocol violation 1 (1.3) 0 (0.0) 1.00
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Table 3. Analyses of clinical and microbiological efficacy
Linezolid group
Trimethoprim/sulfamethoxazole
and rifampicin group Risk difference 95% CI
Clinical follow-up
ITT analysis
success, n (%) 56 (74.7) 59 (78.7) 4.0 29.7 to 17.6
relapse/failure, n (%) 19 (25.3) 16 (21.3)
PP analysis
success, n (%) 54 (81.8) 52 (88.1) 6.3 26.8 to 19.2
relapse/failure, n (%) 12 (18.2) 7 (11.9)
Microbiological follow-up
PP analysis
success, n (%) 26 (78.8) 22 (88.0) 9.2 212.0 to 28.4
persistence, n (%) 7 (21.2) 3 (12.0)
Table 4. ITT outcome analysis by site and severity of MRSA infection
Clinical outcome Linezolid group
Trimethoprim/sulfamethoxazole
and rifampicin group Risk difference 95% CI
Skin and soft tissue infection
success, n (%) 16 (76.2) 20 (83.3) 7.1 217.0 to 31.8
relapse/failure, n (%) 5 (23.8) 4 (16.7)
Surgical site infection
success, n (%) 15 (78.9) 11 (73.3) 25.6 235.6 to 23.2
relapse/failure, n (%) 4 (21.1) 4 (26.7)
Bacteraemia
success, n (%) 6 (66.7) 7 (77.8) 11.1 231.2 to 50.0
relapse/failure, n (%) 3 (33.3) 2 (22.2)
Pneumonia
success, n (%) 6 (75.0) 5 (55.6) 219.4 257.9 to 26.8
relapse/failure, n (%) 2 (25.0) 4 (44.4)
Osteoarticular infection
success, n (%) 5 (55.6) 6 (85.7) 30.1 218.0 to 65.4
relapse/failure, n (%) 4 (44.4) 1 (14.3)
Abdominal
success, n (%) 4 (100.0) 3 (100.0) 0 259.9 to 52.8
relapse/failure, n (%) 0 (0.0) 0 (0.0)
Urinary tract infection
success, n (%) 2 (100.0) 5 (100.0) 0 247.3 to 69.1
relapse/failure, n (%) 0 (0.0) 0 (0.0)
Other
success, n (%) 2 (66.7) 2 (66.7) 0 265.3 to 65.3
relapse/failure, n (%) 1 (33.3) 1 (33.3)
Non-severe infection (n¼62)a
success, n (%) 22 (81.5) 30 (85.7) 4.2 214.6 to 24.8
relapse/failure, n (%) 5 (18.5) 5 (14.3)
Severe infection (n¼53)a
success, n (%) 22 (71.0) 17 (77.3) 6.3 218.9 to 29.1
relapse/failure, n (%) 9 (29.0) 5 (22.7)
Infection associated with deep-seated foci (n¼35)a
success, n (%) 12 (70.6) 12 (66.7) 23.9 233.8 to 26.9
relapse/failure, n (%) 5 (29.4) 6 (33.3)
aCategories determined by site of infection and duration of therapy, as defined in the Methods section.
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between the treatment arms concerning the time to discharge
among hospitalized patients (excluding ambulatory and
deceased patients), as shown in Table 5.
Safety and toxicity
The frequencies of AEs reported, regardless of the causality and
type of AE, were comparable between the treatment arms
Table 5. Mortality and time to discharge
Linezolid
(n¼75)
Trimethoprim/sulfamethoxazole
and rifampicin (n¼75)
Risk
difference 95% CI
Death, n (%) 8 (10.7) 6 (8.0) 22.7 212.8 to 7.2
death before discharge, n (%) 8 (10.7) 3 (4.0) 26.7 216.3 to 1.9
death after discharge, n (%) 0 (0.0) 1 (1.3) 1.3 23.7 to 7.2
death among outpatients, n (%) 0 (0.0) 2 (2.7) 2.7 22.6 to 9.2
Time from inclusion to discharge (days), median (IQR)a 16 (8–36) 12 (6–31)
aAmong non-deceased, hospitalized patients (n¼125; P¼0.83).
Table 6. Safety features in the ITT population
Linezolid group (n¼75)
Trimethoprim/sulfamethoxazole
and rifampicin group (n¼75) Risk difference 95% CI
AEs, n 192 169
patients with at least one AE, n (%) 49 (65.3) 50 (66.7) 1.4 213.8 to 16.4
Type of AE, n (%)
gastrointestinal 72 (37.5) 61 (36.1) 21.4 211.3 to 8.6
cardiovascular 23 (12.0) 24 (14.2) 2.2 24.8 to 9.5
fever 23 (12.0) 18 (10.7) 21.3 28.0 to 5.5
pulmonary 16 (8.3) 7 (4.1) 24.2 29.5 to 0.9
dermatological 15 (7.8) 14 (8.3) 0.5 25.3 to 6.5
haematological 14 (7.3) 10 (5.9) 21.4 26.7 to 4.1
neurological 12 (6.3) 16 (9.5) 3.2 22.4 to 9.3
fall 6 (3.1) 5 (3.0) 20.1 24.1 to 4.0
urological 3 (1.6) 4 (2.4) 0.8 22.4 to 4.5
liver 0 (0.0) 1 (0.6) 0.6 21.4 to 3.3
nephrological 2 (1.0) 3 (1.8) 0.8 22.2 to 4.2
rheumatological 1 (0.5) 0 (0.0) 20.5 22.9 to 1.7
orthopaedic 1 (0.5) 1 (0.6) 0.1 22.4 to 2.8
others 4 (2.1) 5 (3.0) 0.9 22.7 to 5.0
SAEs, n 15 16
number of patients with at least one SAE, n (%) 15 (20.0) 15 (20.0) 0.0 213.0 to 13.0
Type of SAE, n (%)
death 8 (53.3) 6 (37.5) 215.8 247.3 to 19.1
rehospitalization 6 (40.0) 10 (62.5) 22.5 213.0 to 52.9
invalidity 1 (6.7) 0 (0.0) 26.7 230.3 to 13.9
ADRsa, n 4 9
number of patients with at least one ADR, n (%) 4 (5.3) 9 (12.0) 6.7 22.6 to 16.7
Type of ADR, n (%)
gastrointestinal 1 (25.0) 4 (44.4) 19.4 237.8 to 61.0
haematological 1 (25.0) 0 (0.0) 225.0 271.2 to 12.3
nephrological 1 (25.0) 2 (22.2) 22.8 255.4 to 41.0
tongue discoloration 1 (25.0) 0 (0.0) 225.0 271.2 to 12.3
dermatological 0 (0.0) 2 (22.2) 22.2 229.3 to 54.7
neurological 0 (0.0) 1 (11.1) 11.1 238.7 to 44.0
aNo SAE or suspected unexpected serious adverse reaction.
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(Table 6). A total of 192 AEswere documented in the linezolid group
versus 169 in the trimethoprim/sulfamethoxazole and rifampicin
group, with similar proportions of patients who experienced ≥1
AE in both treatment groups (linezolid, 65.3%; trimethoprim/sulfa-
methoxazole and rifampicin, 66.7%). Themost common type of AE
in both groups was of gastrointestinal origin.
SAEs were reported in 15 patients in the linezolid group and 16
in the trimethoprim/sulfamethoxazole and rifampicin group
(Table 6). Four ADRs directly attributed to the study medication
occurred in the linezolid group versus nine in the trimethoprim/
sulfamethoxazole and rifampicin group (P¼0.16).
Discussion
The principal findings of this study were: (i) compared with linezo-
lid, the combination of trimethoprim/sulfamethoxazole and
rifampicin seems to be non-inferior in the treatment of MRSA
infection; (ii) the clinical success rates in both groups were
comparable to those reported in previous clinical trials;15 – 18
(iii) there was no difference between the studied medications
regarding total AEs; and (iv) serious drug-related AEs were rare.
Three systematic reviews have summarized the evidence sup-
porting the use of trimethoprim/sulfamethoxazole for treating
MRSA infections.19 –21 All have suggested that trimethoprim/
sulfamethoxazole may be a useful alternative to vancomycin or
linezolid for the treatment of MRSA infection. The combination
of rifampicin plus trimethoprim/sulfamethoxazole is a theoretic-
ally even more attractive regimen for the treatment of MRSA
infections for a number of reasons, including enhanced and intra-
cellular antistaphylococcal activity, excellent bioavailability and
favourable pharmacodynamics.22,23 The combination is widely
used in several European countries, especially for osteoarticular
infections, although published evidence supporting its use
remains sparse.24,25 Moreover, since these antibiotics are avail-
able as generic agents, they offer substantial cost advantages
over other agents such as linezolid and daptomycin.26 As the
launch of generic linezolid has recently been postponed to late
2016 and tedizolid will be patent-protected against generic ero-
sion for many years, the off-patent combination of trimetho-
prim/sulfamethoxazole plus rifampicin will remain an attractive
and inexpensive alternative oral treatment option for MRSA
infections.
There was no selection of resistance to the study medication
among patientswith follow-up cultures. Nevertheless, we observed
a non-significant trend towards a higher rate ofMRSA eradication in
the combination arm. This is in agreement with one controlled trial
that demonstrated the efficacy of trimethoprim/sulfamethoxazole
plus rifampicin for MRSA decolonization.27 In the present study, the
number and nature of AEs was similar in both arms and consistent
with the known safety profile of the study drugs.7,28,29 However,
five more drug reactions occurred in the combination arm,
although this was statistically non-significant.
Our study has several strengths. First, our study population
included patients with various types of MRSA infection, allowing
us to make comparisons not previously reported.1 Interestingly,
we found a clinically important variation in the success rates for
pneumonia and osteoarticular infection; however, this study
was underpowered to detect statistically significant differences.
Second, following EMA policy, we chose a clinically unambiguous
outcome (clinical cure at 6 weeks after the end of treatment) and
did not focus on earlier primary endpoints, such as ‘cessation of
lesion spread’ or ‘time to clinical stability’.30 Third, our study was
investigator-initiated and did not receive industry sponsoring,
decreasing an important source of potential bias.31
This study also has several limitations. First, the chosen non-
inferiority margin is too wide by current standards (10%–15%)
and the predefined sample size (n¼180) was not reached
due to enrolment challenges despite 5 years of recruitment.
Consequently, the study lost statistical power. Furthermore, the
sample size of this study is too small to determine efficacy advan-
tages based on secondary outcomes such as bacteriological cure,
mortality or length of stay. Nevertheless, we believe that our find-
ings can be used in practice to inform therapeutic decision-
making, since the estimates of treatment effect that were
obtained and the corresponding CIs are robust and clinically
meaningful, supporting the idea that trimethoprim/sulfameth-
oxazole and rifampicin is a suitable alternative compared with
linezolid for a variety of MRSA infections. Second, the study was
open-label and hence subject to the inherent limitations of
this type of study design. Third, the trial was confined to a
highly selected patient population from a single institution in
Switzerland with a specific hyperendemic MRSA strain,32 possibly
limiting the generalizability of the results. Fourth, microbiological
follow-up cultures were performed for only 58 patients, limiting
the evaluation of microbiological failure as a secondary outcome.
In summary, our results suggest that both trimethoprim/
sulfamethoxazole and rifampicin combination therapy and linezo-
lid monotherapy are equally effective for treating patients with
MRSA infection. However, the lower daily cost of the combination
treatment renders it an attractive alternative to oxazolidinones.
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